Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y2S7
UPID:
PDIP2_HUMAN
Alternative names:
38 kDa DNA polymerase delta interaction protein
Alternative UPACC:
Q9Y2S7; B2R846; Q96JE4
Background:
Polymerase delta-interacting protein 2, also known as the 38 kDa DNA polymerase delta interaction protein, plays a crucial role in DNA damage tolerance. It regulates translesion synthesis (TLS) of templates carrying DNA damage lesions such as 8oxoG and abasic sites. This protein may enhance the activity of DNA polymerases involved in TLS, including PRIMPOL and polymerase delta (POLD1).
Therapeutic significance:
Understanding the role of Polymerase delta-interacting protein 2 could open doors to potential therapeutic strategies.